1	A whole blood-based transcriptional risk score for nonobese type 2 diabetes
2	predicts dynamic changes in glucose metabolic traits
3	
4	Running title: Blood-based transcriptional risk score, diabetes
5	
6	Yanan Hou, ^{1,2*} Huajie Dai, ^{1,2*} Na Chen, ^{1,2*} Zhiyun Zhao, ^{1,2*} Qi Wang, ^{1,2} Tianzhichao
7	Hou, ^{1,2} Jie Zheng, ^{1,2} Tiange Wang, ^{1,2} Mian Li, ^{1,2} Hong Lin, ^{1,2} Shuangyuan Wang, ^{1,2}
8	Ruizhi Zheng, ^{1,2} Jieli Lu, ^{1,2} Yu Xu, ^{1,2} Yuhong Chen, ^{1,2} Ruixin Liu, ^{1,2} Guang Ning, ^{1,2}
9	Weiqing Wang, ^{1,2} Yufang Bi, ^{1,2†} Jiqiu Wang, ^{1,2†} Min Xu ^{1,2†}
10	
11	Author affiliations:
12	1. Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine
13	and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of
14	Medicine, Shanghai, China;
15	2. Shanghai National Clinical Research Center for metabolic Diseases, Key
16	Laboratory for Endocrine and Metabolic Diseases of the National Health Commission
17	of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key
18	Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University
19	School of Medicine, Shanghai, China.
20	
21	* These authors contributed equally to the work

^{22 &}lt;sup>†</sup> These authors co-supervised the work NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

0	\sim
Ζ	3

24 **†Address of Correspondence:**

25	Min Xu,	MD&PhD,	Professor	of medicine,	Shanghai I	National	Clinical	Research

- 26 Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and
- 27 Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of
- 28 Medicine, Shanghai, 200025, China. E-mail: della.xumin@shsmu.edu.cn;

- 30 Jiqiu Wang, MD&PhD, Professor of medicine, Department of Endocrine and
- 31 Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin
- 32 Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
- 33 200025. Email: wangjq@shsmu.edu.cn;
- 34

35 Iulang Di, MD&Find, Frolessor of medicine, Department of Endo	indocrine and
--	---------------

- 36 Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin
- 37 Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- 38 Email: byf10784@rjh.com.cn.

39 Abstract

40	Background: The performance of peripheral blood transcriptional markers in
41	evaluating the risk of type 2 diabetes (T2D) with normal weight is unknown. We
42	developed a whole blood-based transcriptional risk score (wb-TRS) for nonobese T2D
43	and assessed its contributions to disease risk and dynamic changes in glucose
44	metabolism.
45	Methods and findings: We developed the wb-TRS in 1105 participants aged ≥ 40
46	years and in normal weight for up to 10 years from a well-defined community-based
47	cohort with blood transcriptome data and validated it in an external dataset (253
48	overweight/obese participants from a dietary intervention trial with 3 repeated
49	transcriptome data). Potential biology significance and causal inference were also
50	explored. The wb-TRS included 144 transcripts. Compared to the lowest tertile, wb-
51	TRS in tertile 3 associated with 8.68-folds (95% confidence interval [CI], 3.51-21.5),
52	and each 1-unit increment associated with 2.57-folds (95% CI, 1.86-3.56) higher risk
53	of nonobese T2D, after adjustments for traditional risk factors. Furthermore, baseline
54	wb-TRS was significantly associated with dynamic changes in average, daytime,
55	nighttime and 24h glucose and HbA1c, and area under the curve of glucose measured
56	in the continuous glucose monitoring during 6-month of intervention. The wb-TRS
57	improved the predicting performance for nonobese T2D in a model with fasting
58	glucose, triglycerides and demographic and anthropometric parameters. Mitch
59	analysis implicated oxidative phosphorylation, cholesterol metabolism and mTORC1
60	signaling involved in nonobese T2D pathogenesis. Transcriptome-wide Mendelian

- 61 randomization supported causal effects of gene transcripts such as RAB1A and
- 62 GCC1-PAX4 on nonobese T2D risk.
- 63 **Conclusions:** A whole blood based nonobese T2D associated TRS was validated to
- 64 predict dynamic changes in glucose metabolism. These findings also suggested
- 65 several genes and biological pathways that might involve in the pathogenesis of
- 66 nonobese T2D.
- 67
- 68 Keywords: nonobese type 2 diabetes, glucose metabolic traits, blood transcriptome,
- 69 transcriptional risk score, risk prediction, transcriptome-wide Mendelian
- 70 randomization

71 Abbreviations:

- 72 AUC area under the curve
- 73 BMI body mass index
- 74 CPM count per million
- 75 CI confidence interval
- 76 DBP diastolic blood pressure
- 77 DPMH Dietary Pattern and Metabolic Health
- 78 eQTL expression quantitative trait locus
- 79 GEE generalized estimating equation
- 80 HbA1c hemoglobin A1c
- 81 HOMA-IR homeostasis model assessment of insulin resistance
- 82 HOMA- β homeostasis model assessment of beta cell function
- 83 HDL-C high-density lipoprotein cholesterol
- 84 MET metabolic equivalent of task
- 85 Mitch analysis a multi-contrast gene set enrichment analysis
- 86 LDL-C low-density lipoprotein cholesterol
- 87 LASSO least absolute shrinkage and selection operator
- 88 OGTT oral glucose tolerance test
- 89 OR odds ratio
- 90 RCS restricted cubic spline
- 91 RNA-seq RNA sequencing
- 92 SBP systolic blood pressure

- 93 T2D Type 2 diabetes
- 94 TRS transcriptional risk score
- 95 TWMR Transcriptome-wide Mendelian randomization
- 96 TSGE Tissue-specific gene expression

97 Author summary

98 Why was this study done?

99	• Blood transcriptome has been emerging as a potential novel approach to
100	understand contribution of genes expression to biological functions and to
101	identify key genes that confer to complex disease susceptibility, such as
102	cardiovascular, psychiatry and chronic obstructive pulmonary disease.
103	• Rare studies have investigated the performance of the peripheral blood
104	transcriptional markers in evaluating the risk and prediction of type 2 diabetes
105	(T2D).
106	What did the researchers do and find?
107	• We developed a whole blood-based transcriptional risk score (wb-TRS) for T2D
108	risk in a longitudinal community-based cohort.
109	• The wb-TRS was positively associated with risk of T2D and glucose metabolic
110	traits. Furthermore, the baseline wb-TRS as well associated with dynamic
111	changes of glucose metabolism measured in the continuous glucose monitoring in
112	response to 6-month dietary intervention.
113	• The wb-TRS performed better and was complementary to fasting glucose,
114	triglycerides and the demographic and anthropometric factors in predicting T2D.
115	• Transcriptome-wide Mendelian randomization and Mitch analysis and supported
116	several gene transcripts (RAB1A and GCC1-PAX4) and biological pathways
117	(oxidative phosphorylation, mTORC1 signaling, and cholesterol metabolism) that
118	might involve in the pathogenesis of T2D.

119 What do these findings mean?

120	•	Blood transcriptome highly related to and reflect risk of T2D and predict dynamic
121		changes in glucose metabolism. It may lend insight into discerning potential
122		causal genes and biological mechanisms in the pathogenesis of nonobese T2D.

123 Introduction

124	Type 2 diabetes (T2D) has been a worldwide epidemic in recent decades leading high
125	rates of early mortality and co-morbidity and possessing a considerable health and
126	economic burden for the patients [1]. Early prediction and detection of individuals
127	with glucose dysregulation and type 2 diabetes is extremely important for the
128	prevention and management of these disorders. Previous reliable risk prediction
129	models usually comprise the anthropometric measurements and traditional laboratory
130	data. Recent studies have provided evidence of the prediction effect by including
131	genetic factors and metabolic molecules in the models [2, 3]. However, as an essential
132	biological and pathogenesis process, the performance and effect of gene transcription
133	profile in evaluating T2D risk has not been well examined yet [4].
134	Tissue-specific gene expression (TSGE) is phenotypic manifestations integrating
135	both genetic and environmental variations, which confers further insights to the
136	intricate pathophysiology of diseases [5]. However, most tissues such as pancreas,
137	liver, etc. cannot be readily obtained without invasive procedures in humans. As an
138	alternative, blood transcriptome could better predict TSGE for $\sim 60\%$ of the genes on
139	average, with up to 81.7% in skeletal muscle, 71.5% in visceral adipose tissue, and
140	52.4% in pancreas [5]. Blood transcriptome has been emerging as a potential novel
141	approach for complex diseases to understand contribution of genes expression to
142	biological functions and to identify key genes that confer to complex disease
143	susceptibility [6-9], such as cardiovascular, psychiatry and chronic obstructive
144	pulmonary disease. However, rare studies have investigated the performance of the

145	peripheral blood transcriptional markers in evaluating the risk and prediction of T2D.
146	Though obesity is one of its major risk factors, the T2D risk is still high in normal
147	weight, especially in east Asians. One in three of diagnosed T2D had a body mass
148	index (BMI) of less than 25 kg/m ² , indicating the importance of metabolic health in
149	the pathogenesis regardless of adiposity [10, 11]. Studies focused on refining T2D
150	subtypes highlighting nonobese T2D, which characterized by a lower BMI, early
151	onset of age, severe insulin deficiency, and serious complications [12-15]. The east
152	Asians developed T2D risk at a relatively lower level of BMI [16]. The existing
153	evidence indicated that specific genes, pathways, and biological mechanisms might
154	underly the pathophysiology of nonobese T2D.
155	Thus, we developed a whole blood-based transcriptional risk score (wb-TRS) of
156	nonobese T2D in 1105 participants aged 40 and above in an ongoing longitudinal
157	Chinese cohort, in which the participants have maintained normal weight for up to 10
158	years. To validate its performance in a more general age and BMI range, we examined
159	its predictive value on dynamic change in glucose metabolism in an independent
160	external dataset (253 young overweight/obese participants from a dietary intervention
161	trial with 3 repeated whole blood-based transcriptome data). Furthermore, we
162	explored the potential genes and biological pathways that may conferred disease's
163	susceptibility and pathogenesis and performed transcriptome-wide Mendelian
164	randomization (TWMR) to investigate additional evidence supporting a causal links
165	between gene transcripts and T2D risk in a separate East Asian population and
166	European population. The wb-TRS would provide an additional layer of biological

167 interpretability for T2D.

168

169 Methods

170 Study population

- 171 The current analysis was based on one of the follow-up circles of our previous
- 172 community-based cohort of in Shanghai, China [17-19]. Briefly, all the participants
- 173 have taken part in a comprehensive examination that included a questionnaire and
- biochemical measurements at baseline in 2008-2009, the first (5- years) in 2013 and
- second (10-years) follow-up visits in 2018, respectively. The participants with known
- 176 T2D before baseline examination were excluded.
- 177 According to the information at baseline and the 5-year follow-up examination, at
- the 10-year follow-up visit, we selected the participants whose BMI <25kg/m² in past
- 179 10 years to take part in the examination sequentially and collected the whole blood
- 180 samples for RNA-sequencing (RNA-seq). Finally, 1183 participants attended the
- 181 follow-up visit finished the blood sampling for RNA-seq and 1105 with high-quality
- 182 sequencing data were included in the present analysis. The flowchart of study
- 183 participants was shown in Fig S1.
- 184 The study protocol was approved by the Institutional Review Board of Rui-Jin
- 185 Hospital affiliated to Shanghai Jiao Tong University School of Medicine. All
- 186 participants gave the written consents for the study.
- 187

188 Data collection

189	A standard questionnaire was adopted to collect information on sociodemographic
190	characteristics, disease and medical history, and lifestyles. Current smoking or
191	drinking was defined as participants consumed cigarettes or alcohol regularly in the
192	past 6 months. We used Global Physical Activity Questionnaire (GPAQ) to obtain
193	frequency, duration, and intensity of physical activity. Physical activity level was
194	evaluated as Metabolic Equivalent of Task (MET) minutes per week. Body height,
195	weight and waist circumference were measured using a standard protocol. BMI was
196	calculated as body weight (kg) divided by squared height (m ²). Three seated systolic-
197	and diastolic blood pressure (SBP and DBP) were measured (Omron HEM-752
198	Fuzzy; Omron, Dalian, China) at the non-dominant arm consecutively with 1 min
199	interval after at least 5-minutes rest. The three readings were averaged for analysis.
200	
201	Biochemical measurements
202	Venous blood samples were obtained after an overnight fasting (>10 hours). All
203	participants underwent a 75 g oral glucose tolerance test (OGTT). Fasting and 2h-
204	OGTT glucose was measured using glucose oxidase method on an automated
205	analyzer (ADVIA-1650 Chemistry System; Bayer); fasting and 2h-OGTT insulin
206	using electrochemiluminescence assay on an automated analyzer (Roche Diagnostics
207	Basel, Switzerland); and hemoglobin A1c (HbA1c) using high pressure liquid
207 208	Basel, Switzerland); and hemoglobin A1c (HbA1c) using high pressure liquid chromatography on an automated analyzer (VARIANT II Hemoglobin Testing
207 208 209	Basel, Switzerland); and hemoglobin A1c (HbA1c) using high pressure liquid chromatography on an automated analyzer (VARIANT II Hemoglobin Testing System, Bio-Rad Laboratories). Fasting triglycerides, total cholesterol, low-density

automated analyzer (ADVIA-1650 Chemistry System; Bayer).

212

213 **Definition of T2D**

- T2D was diagnosed as fasting glucose \geq 7.0 mmol/l, 2h-OGTT glucose \geq 11.1 mmol/l,
- HbA1c \geq 6.5%, and/or taking antidiabetic therapy [20]. The homeostasis model
- assessment of insulin resistance (HOMA-IR) was calculated as fasting glucose
- $(mmol/l) \times fasting insulin (uIU/ml) / 22.5$. The HOMA index for beta cell function
- (HOMA- β) was calculated as 20 × fasting insulin (uIU/ml) / (fasting glucose

219 [mmol/l]-3.5).

- 221 **RNA-seq**
- 222 The whole blood samples were collected by using the Paxgene RNA tubes according
- to the manufacture's protocol, shipped and stored in -80°C before RNA extracting.
- 224 RNA was extracted by using the PAXgene Blood miRNA Kit Secondary BD
- Hemogard Closures (Catalog no 763134, Qiagen, Germany). Nanodrop One
- 226 spectrometer (Thermo Fisher Scientific Inc., USA) and Qubit®3.0 Fluorometer (Life
- 227 Technologies, CA, USA) were used to determine RNA purity and concentration.
- 228 Isolated total RNA was analyzed on an Agilent Bioanalyzer 2100 (Agilent
- technologies, Santa Clara, CA, US) for RNA integrity number quality check. We
- excluded 78 samples with low RNA quality. 1ug RNA was used as input material for
- the RNA-seq preparations.
- 232 RNA-seq strand-specific libraries were constructed using the VAHTS Total RNA-

233	seq (H/M/R) Library Prep Kit (Vazyme, China). Briefly, RNA was purified by
234	magnetic beads after removal of rRNA. Then RNA was fragmented into small pieces
235	using divalent cations for 8 minutes at 94°C. The cleaved RNA fragments were copied
236	into first strand cDNA using reverse transcriptase and random primers. Second strand
237	cDNA synthesis was subsequently performed using DNA Polymerase I and RNase H.
238	These cDNA fragments then go through the end repair process, addition of a single
239	'A' base, and ligation of the adapters. The products were purified and enriched by
240	PCR to create the final cDNA library. Purified libraries were quantified and validated
241	by Qubit® 3.0 Fluorometer and Agilent 2100 bioanalyzer to confirm the insert size
242	and calculate the mole concentration. Cluster was generated by cBot after the library
243	diluted to 10 pM. Cluster were then sequenced in 150-bp paired-end mode on the
244	Illumina NovaSeq 6000 platform (Illumina, USA) generating arounds 12 gigabases
245	(Gb) reads per samples.
246	The base call and sequence quality across all generated FASTQ data was evaluated
247	using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). We
248	removed adapters, low quality reads, ribosome RNA reads, and reads with a sequence
249	length less than 25 to obtain clean reads. Clean reads were mapped to human
250	GRCh38.102 with Hisat2 (Hierarchical Indexing for Spliced Alignment of
251	Transcripts, version 2.0.5) using default parameters. Overall, we obtained RNA-seq
252	data with base mass (Q30) \geq 90%, average mapped ratio was 94%. Count data were
253	filtered to include transcripts with > 1count per million (CPM) in 99% of T2D cases
254	or non-T2D controls.

255

256 wb-TRS construction

257	The 1105 participants with blood-based transcriptome data were randomly assigned to
258	training (75%) and testing (25%) dataset (R package caret) (Fig 1). To identify genes
259	that could better distinguish the diseases status, we included the transcripts with gene
260	expression level >1CPM in 99% of T2D cases or non-T2D controls and with a
261	nominal difference P value <0.01 between these two groups in the wb-TRS features
262	screening progress (n=757 gene transcripts). The wb-TRS construction was carried
263	out in the training dataset and validated in testing and an external dataset. A multi-
264	contrast gene set enrichment (Mitch) analysis [21] and Reactome pathway analysis
265	[22] were performed to identify key genes and pathways.
266	In detail, we performed a penalized logistic regression framework using R package
267	glmnet to develop the wb-TRS for nonobese T2D. We adopted the least absolute
268	shrinkage and selection operator (LASSO) regression model to model training, which
269	provides shrinks coefficients toward zero and automated feature selection. We
270	adopted 10-fold cross-validation procedure to determine the lambda (0.006) that
271	maximized the area under curve (AUC) for predicting T2D (Fig S2). The regression
272	model with maximum AUC was used to calculate the wb-TRS.
273	

274 Statistical analysis

275 Multivariable logistic regression analyses were used to assess the risk of nonobese

T2D in relation to wb-TRS. Odds ratio (OR) and the corresponding 95% confidence

277	interval (CI) were calculated. The linear regression model was to assess the
278	association of wb-TRS with the cardiometabolic traits. The restricted cubic spline
279	(RCS) analysis was used to test any nonlinear associations between wb-TRS and
280	glucose metabolism. The receiver operator characteristic curves (ROC) were used to
281	evaluate and compare the predictive values of 6 models for nonobese T2D (R package
282	pROC) including: 1. primary model (age, sex, BMI and family history of diabetes); 2.
283	wb-TRS model; 3. fasting glucose and triglycerides model; 4. primary model adding
284	fasting glucose and triglycerides (full); 5. primary model adding wb-TRS; 6. primary
285	model adding fasting glucose and triglycerides (full), and wb-TRS.
286	
287	Independent validation
288	To validate the predictive value of wb-TRS for the dynamic changes in glucose
289	metabolism, we performed analysis using data of 3 repeated blood-based
290	transcriptome data and glucose metabolism in the Dietary Pattern and Metabolic
291	Health (DPMH) study, a parallel-arm randomized controlled feeding trial conducted
292	in 2019 (URL: https://www. clinicaltrials.gov; Unique identifier: NCT03856762)
293	[23]. A total of 253 overweight/obese participants (aged 25 to 60 years, BMI \geq
294	24.0 kg/m ² , fasting glucose \geq 5.6 mmol/l) with transcriptome data and glucose
295	metabolic traits at baseline, the first (3-months) and second (6-months) follow-up
296	visits were included in the validation analysis. The whole blood RNA was collected
297	and underwent RNA-seq following the same procedure with the above cohort study.
298	We adopted generalized estimating equations (GEE) models were to assess the

299	association of three-repeated measurements of wb-TRS with three-repeated
300	measurements of the glucose metabolism during the 6-months intervention. We
301	further fixed the generalized linear models to assess the effects of baseline wb-TRS
302	on dynamic changes of glucose metabolism at 3- and 6- months of intervention.
303	
304	The biological pathway and mechanism analysis
305	To gain biological insight behind the wb-TRS, we performed several bioinformatics
306	analyses. We divided the participants in the initial cohort into 3 subgroups based on
307	wb-TRS tertiles. We performed a multi-contrast gene set enrichment analysis by using
308	R package mitch (v.1.4.0). The Mitch analysis uses a rank-MANOVA statistical
309	approach to identify sets of genes that exhibit joint enrichment or divergent responses
310	across multiple contrast. The input data was the log2(fold change) of all detected
311	transcripts (n=54,458, including protein coding gene, lncRNA, and snRNA) for
312	comparison between the bottom and mid tertile, and the top and mid tertile,
313	respectively. The input genesets provided were 50 genesets: h.all.v7.5.1.symbols.gmt
314	in Molecular Signatures Database (MSigDB). Enrichment score (ES) was obtained
315	and ranged from -1 to 1. Meanwhile, we used the 144 gene transcripts included in the
316	wb-TRS as input profiles to perform Reactome pathway analysis on reactome website
317	(https://reactome.org/PathwayBrowser/#TOOL=AT).
318	

319 Transcriptome-wide Mendelian randomization

320 We performed a two-sample transcriptome-wide Mendelian randomization (TWMR)

321	to identify causal associations of gene transcripts included in wb-TRS with T2D risk
322	using the TwoSampleMR. The summary statistics of genome-wide association study
323	of T2D was from the Asian Genetic Epidemiology Network (AGEN) [16] and the
324	DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) [24], respectively.
325	We selected the significant expression quantitative trait loci (eQTLs with $P < 5 \times 10^{-8}$)
326	obtained from eQTLGen Consortium [25] and with linkage disequilibrium (LD) based
327	on $r^2 < 0.01$ as valid instruments variants (IVs) used in TWMR. When no shared
328	eQTLs were available between exposures and outcomes, proxies with LD $r^2 > 0.8$
329	were substituted. TWMR causality tests were performed using the inverse variance
330	weighted method by meta-analyzing the effect of each IV from Wald ratio.
331	Heterogeneity and pleiotropy of the results were assessed using Cochran's Q statistic
332	or MR-Egger intercept, respectively.
333	All analyses were performed using SAS (version 9.3; SAS Institute, Cary, NC,
334	USA) and R software (version 3.5.1; R Core Team). A two-sided P value < 0.05 was
335	considered statistically significant.
336	
337	Results
338	Clinical characteristics of study participants
339	In the 1105 participants, 305 were defined as nonobese T2D (27.6%), 737 (66.7%)

- were women, with an average age of 64.5 (standard deviation [SD], 7.0) years old.
- 341 The balanced clinical characteristics between the training and testing dataset indicated
- a low risk of selection bias introduced by random sampling (Table S1).

343

344 Construction and distribution of wb-TRS

- 345 Finally, 144 important features (gene transcripts) were included in the wb-TRS, which
- 346 weights were displayed in **Table S2**. The wb-TRS was estimated as gene expression
- 347 level of transcript1 \times weight1 + gene expression level of transcript2 \times weight2 +...+
- 348 gene expression level of transcript $144 \times \text{weight} 144$.
- 349 The wb-TRS was positively associated with age (β 0.98, SE 0.15, P<0.0001), and
- 350 was slightly higher in men (-1.7, SD 1.5) than that in women (-2.1, SD 1.3). The mean
- wb-TRS was -0.5 (SD 0.9) in T2D and -2.5 (SD 1.1) in non-diabetes in training
- dataset, and -0.9 (SD 1.4) in T2D and -2.4 (SD 1.3) in non-diabetes in testing dataset.
- 353 Fig S3 displays the violin plot of the wb-TRS and gene transcripts most negatively
- 354 (FUOM) and positively (RPF1) associated with T2D in training dataset.

355

356 Association of wb-TRS with nonobese T2D

- 357 **Table 1** shows association of wb-TRS with nonobese T2D risk in testing dataset. Each
- 358 1-unit increment in wb-TRS (one score) was associated with a 2.49-folds higher risk
- of nonobese T2D (95%CI 1.84-3.36), after adjustments of age, sex, BMI and family
- 360 history of diabetes. Additional adjustment for potential confounders including
- 361 lifestyles, education levels, waist circumference, SBP and DBP, and lipids profiles did
- not change the results appreciably (OR 2.57, 95% CI 1.86-3.56). Specifically, each 1-
- 363 unit increment in wb-TRS was associated with 3.40-folds higher risk of newly
- diagnosed nonobese T2D (95%CI 2.00-5.81), and 2.33-folds higher risk of diabetes

365	with durat	ion \geq 5 years	(95%CI 1.56-3.48). Compared	d with the	bottom tertile, the
-----	------------	--------------------	------------------	-------------	------------	---------------------

- middle or top tertile of wb-TRS was associated with 2.46- (95% CI 0.95-6.35) and
- 367 8.68-folds (95% CI 3.51-21.5) higher risk of nonobese T2D.
- 368 We then examined the associations of wb-TRS with nonobese T2D risk stratified
- 369 by several traditional risk factors of T2D (Fig S4). A stronger association was
- identified in age <65 years and women (a marginal interaction between TRS and sex
- 371 was observed with P for interaction =0.051).
- 372

373 Association of wb-TRS with glucose metabolism

- 374 In both training and testing dataset, the wb-TRS was positively associated with fasting
- glucose, 2h-OGTT glucose, and HbA1c; but inversely associated with HOMA-β, in
- the fully adjusted model (Table 2). The RCS analysis showed similar results, except
- 377 for that it demonstrated a J shaped relationships between wb-TRS and HbA1c and

logHOMA β (all P for non-linear ≤0.001) (Fig 2).

- 379 The GEE analysis by using the 3 repeated measurements of glucose metabolism
- traits and wb-TRS at baseline, 3 month- and 6 month-visits during the intervention
- showed that each 1-unit increment in wb-TRS was associated with 0.11mmol/l (SE
- 382 0.05) and 0.15mmol/l (SE 0.02) increment of 1h- and 2h-OGTT glucose, respectively.
- 383 Interestingly, the baseline wb-TRS significantly affected the dynamic changes of
- cardiometabolic traits at 6- months of dietary intervention (Table 3). Baseline wb-
- 385 TRS significantly associated with changes in average daytime, nighttime and 24h
- 386 glucose and HbA1c levels and the AUC of glucose measured in the continuous

387 glucose monitoring at 6 month of diet intervention (all P<0.03).

388

389 wb-TRS performed well in predicting T2D

- 390 In both training and testing dataset, wb-TRS performed well in predicting nonobese
- 391 T2D, even when adding wb-TRS into a model with fasting glucose, triglycerides, and
- the primary model (Fig 3). In total dataset, a model with wb-TRS along with fasting
- 393 glucose, triglycerides, and variables in primary model significantly improved the
- AUC (0.93), as compared to the primary model (AUC = 0.65), the fasting glucose and
- triglycerides model (AUC=0.82), and the fasting glucose, triglycerides adding to the
- primary model (full model, AUC =0.84) for predicting T2D (Table S3). The wb-TRS
- improved predicting performance in a model with fasting glucose, triglycerides, and
- the demographic and anthropometry parameters (AUC-TRS+full: 0.93 [0.91-0.95] vs.
- 399 AUC-full: 0.84 [95% CI 0.81-0.87]; P < 0.0001).
- 400

401 The biological pathway and mechanism analysis

402 The Mitch analysis compared the bottom versus middle and top versus middle tertiles

- 403 of wb-TRS (Fig 4). The top versus middle tertile group comparison demonstrated
- 404 downregulation of MYC target V2, and the bottom versus middle tertile group
- 405 comparison demonstrated upregulation of oxidative phosphorylation, mTORC1
- 406 signaling, cholesterol metabolism, peroxisome, fatty acid metabolism, etc. (Fig 4A).
- 407 The significant metabolic pathways were displayed in Fig 4B. The small GTPase
- 408 (RAB1A gene) enriched in mTORC1 signaling, fatty acid oxidation gene (CPT1A)

409	enriched in	oxidative 1	phosphory	lation	pathway.	and cholesterol	efflux gene	(ABCA1)
TUJ			phopphol i	Includi	pauring			

- 410 enriched in cholesterol metabolism pathway.
- 411 The Reactome analyses suggested that the 144 gene transcripts included in wb-TRS
- 412 were involved in NR1H2 (LXR β) and NR1H3 (LXR α) regulate gene expression to
- 413 limit cholesterol uptake, regulation of lipid metabolism by PPAR alpha pathway, etc.
- 414 The cholesterol uptake suppression gene (MYLIP) enriched in LXR β and LXR α
- 415 regulate gene expression to limit cholesterol uptake pathway (**Table S4**).
- 416

417 Causal relationships between gene transcripts included in wb_TRS and T2D

- 418 Gene transcripts (n=19) with no validated IVs were removed from TWMR analysis.
- 419 Among the 125 remaining gene transcripts, 6 gene transcripts (GCC1-PAX4,
- 420 AKR1A1, AAMP, RAB1A, ITGA1, and ZNF639) were causally linked to T2D risk in
- 421 AGEN and 1 gene transcript (RAB1A) was successfully validated in DIAGRAM
- 422 (Table S5, P < 0.0004 = 0.05/125, where 125 corresponds to the number of gene
- 423 transcripts tested in TWMR). Specifically, RAB1A enriched in mTOCR1 signaling is
- 424 causally associated with 38% (95% CI: 1.18-1.62, $P=8.0\times10^{-5}$) and 47% (95% CI:
- 425 1.21-1.77, P=5.4×10⁻⁵) increase of T2D risk in AGEN and DIAGRAM, respectively.
- 426 GCC1-RAX4 converted 17% decrease of T2D risk (95% CI: 0.80-0.88, P=5.2×10⁻¹⁵)
- 427 in AGEN.

428

429 Discussion

430 In this study, we developed a wb-TRS for T2D risk in a longitudinal community-

431	based cohort in which the participants were middle aged and elderly and maintained
432	nonobese for up to 10 years. The wb-TRS was positively associated with risk of T2D
433	and could reflect dynamic change in glucose metabolism such as fasting and 2h-post
434	loading glucose, HbA1c, and beta cell dysfunction in the observational cohort.
435	Furthermore, the baseline wb-TRS well associated with the changes of glucose
436	metabolism measured in the continuous glucose monitoring in response to the 6-
437	month dietary intervention in a panel of younger and overweight participants. The
438	wb-TRS performed better and was a complementarity to fasting glucose, triglycerides
439	and the demographic and anthropometric factors in predicting T2D. The wb-TRS
440	supported several gene transcripts (RAB1A and GCC1-RAX4) and biological
441	pathways (oxidative phosphorylation, cholesterol metabolism, and mTORC1
442	signaling) that might involve in the etiology of nonobese T2D.
442 443	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of
442 443 444	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits
442 443 444 445	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits by using peripheral blood transcriptional markers. Recently, several studies proposed
442 443 444 445 446	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits by using peripheral blood transcriptional markers. Recently, several studies proposed the concept of TRS or polygenetic TRS, which used cumulative gene expression
442 443 444 445 446 447	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits by using peripheral blood transcriptional markers. Recently, several studies proposed the concept of TRS or polygenetic TRS, which used cumulative gene expression information to provide an additional layer of biological interpretability and performed
 442 443 444 445 446 447 448 	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits by using peripheral blood transcriptional markers. Recently, several studies proposed the concept of TRS or polygenetic TRS, which used cumulative gene expression information to provide an additional layer of biological interpretability and performed better than both traditional risk factors and polygenic risk score for predicting Crohn's
 442 443 444 445 446 447 448 449 	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits by using peripheral blood transcriptional markers. Recently, several studies proposed the concept of TRS or polygenetic TRS, which used cumulative gene expression information to provide an additional layer of biological interpretability and performed better than both traditional risk factors and polygenic risk score for predicting Crohn's disease, chronic obstructive pulmonary disease, and lung function [8, 26-28]. Our
 442 443 444 445 446 447 448 449 450 	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits by using peripheral blood transcriptional markers. Recently, several studies proposed the concept of TRS or polygenetic TRS, which used cumulative gene expression information to provide an additional layer of biological interpretability and performed better than both traditional risk factors and polygenic risk score for predicting Crohn's disease, chronic obstructive pulmonary disease, and lung function [8, 26-28]. Our study is in line with previous studies showing transcriptional variance is a reliable
 442 443 444 445 446 447 448 449 450 451 	signaling) that might involve in the etiology of nonobese T2D. To the best of our knowledge, the present study is the first to examine the effects of wb-TRS on nonobese T2D risk and dynamic change of related cardiometabolic traits by using peripheral blood transcriptional markers. Recently, several studies proposed the concept of TRS or polygenetic TRS, which used cumulative gene expression information to provide an additional layer of biological interpretability and performed better than both traditional risk factors and polygenic risk score for predicting Crohn's disease, chronic obstructive pulmonary disease, and lung function [8, 26-28]. Our study is in line with previous studies showing transcriptional variance is a reliable intermediary mediating associations of genotypes with complex phenotypes [5, 6, 29]

453 promising better predictive effect on T2D and the dynamic changes in related

454 cardiometabolic traits.

455	In our study, the wb-TRS could well predict dynamic changes in glucose
456	metabolism in response to 6 months of 25% calorie restriction dietary intervention in
457	overweight/obese subjects [23]. In our trial (DPMH), a 25% calorie restriction
458	produced an appreciable weight reduction and improved glucose homeostasis [23].
459	Calorie restriction improves cardiometabolic risk including atherogenic dyslipidemia
460	(elevated triglycerides and fasting glucose, reduced HDL-C, diabetes, hypertension,
461	and large waist circumference) [30, 31]. Previous findings from the Comprehensive
462	Assessment of Long-term Effects of Reducing Intake of Energy (CALERIETM)
463	study, a 24-month, multicenter, randomized controlled calorie restriction trial, showed
464	that in young to middle aged, normal to slightly overweight adults, two years of >12%
465	caloric restriction improved traditional cardiometabolic risk factors within ranges
466	considered normal [31]. Recent study suggested that in healthy adults without obesity,
467	a 12% calorie restriction led to improved reducing inflammation and branched chain
468	amino acids and shifting lipoproteins from atherogenic to cholesterol transporting
469	[32]. We suspected that the genes and pathways included in the wb-TRS played key
470	roles in cardiometabolic beneficial effects in response to the calorie restriction dietary
471	intervention, which might help to explore the underlying mechanisms for the
472	beneficial effects.
473	Our results indicated several potential pathways and gene transcripts that might

474 involve in the etiology process of nonobese T2D, which suggested that transcriptional

475	information in blood could be capable of reflecting diseases risk and could bridge the
476	knowledge gap on how gene expression affects nonobese T2D. We found mTORC1
477	signaling directly regulates β -cell functional maturation and identity maintenance
478	[33]. Of note, by using TWMR analysis, we also demonstrated that the RAB1A gene
479	encoding a small GTPase, which is enriched in mTORC1 signaling, was positively
480	and causally associated with T2D risk in both east Asians and Europeans. Another
481	T2D susceptibily gene (GCC1-PAX4) was also causally associated with T2D risk in
482	east Asians [34]. PAX4 implicated in a Japanese case of maturity onset diabetes of the
483	young that is only 30kb further away from GCC1 is an outstanding candidate for T2D
484	given its involvement in pancreatic islet development [34]. This molecular
485	mechanism of nonobese T2D was consistent with that the nonobese Asian Indians
486	with young-onset diabetes have lower genetically determined beta cell function [35].
487	We identified oxidative phosphorylation and cholesterol metabolism pathways
488	involved in nonobese T2D. Of note, fatty acid oxidation gene (CPT1A) enriched in
489	oxidative phosphorylation pathway might mediate mitochondrial overload increasing
490	insulin resistance in muscle, lipid accumulation in liver, and lipotoxicity in pancreatic
491	beta cells thus involved in homeostasis of glucose metabolism [36, 37]. Cholesterol
492	efflux gene (ABCA1) enriched in cholesterol metabolism pathway might via its
493	downregulation to inhibit cholesterol transportion to HDL and excretion to bile and
494	faeces, and then increase lipids profile and deteriorates cardio-metabolism [38].
495	In Reactome analysis, cholesterol uptake suppression gene (MYLIP) enriched in
496	LXR β and LXR α regulate gene expression to limit cholesterol uptake pathway.

Inhibition of MYLIP increases cellular cholesterol accumulation and leads to
pancreatic β-cell dysfunction and insulin resistance [39]. We suspected that
cholesterol metabolism in liver and pancreas and beta cell dysfunction involved in
nonobese T2D but warrant further study in the future. Besides, the consistency of
transcriptional levels of these genes in whole-blood and specific tissue is another
interesting issue.

The major strengths of our current study lie in our adopted analytical approaches as 503 well as the well-characterized study cohorts. We adopted high-throughput RNA-seq 504 505 technology, a penalized regression model with 10-fold cross validation method to develop the wb-TRS, and successfully validated its performance in an independent 506 external cohort, which guaranteed the statistical power and robustness of our findings 507 508 and conclusions. In terms of the study cohorts, our initial cohort included T2D whose BMI maintained normal for up to 10 years, which are expected to better capture 509 underling pathophysiology mechanism of nonobese T2D. 510 511 Our study, however, also has several limitations. First, transcriptome data were measured only at 10 years follow-up visit in initial cohort, which could not establish a 512 causal relationship between the wb-TRS and nonobese T2D risk. It would also be 513 greater interesting to see whether transcriptional change would continue to be 514 515 associated with incidence risk of nonobese T2D. Second, complex diseases are final phenotypes of transcriptional dysregulation in multiple tissues. Though an appreciable

- 516 phenotypes of transcriptional dysregulation in multiple tissues. Though an appreciable
- 517 proportion of genes expressed in tissues is expressed in peripheral whole blood [40], it
- still should be better to interpret the present wb-TRS as one of potential essential

519	complementary prediction tools for nonobese T2D, rather than presenting an exact
520	pathophysiological process of it. Nevertheless, the individual's blood transcriptome
521	performed well in predicting tissue-specific expression and performed as well as
522	measured tissue expression in predicting complex diseases [5]. Third, we did not
523	incorporate metabolic markers in the analysis, which restrained us from comparing
524	the predictive effect between them. Jointly considering the genetic and metabolic
525	profiling and transcriptional level of alterations would provide more precise and
526	accurate evaluation of T2D risk and prediction efficacy. Last, both the initial and
527	vailidation cohort consisted of participants from east Asia, cautions should be
528	exercised to generalize the finding to other ethnicity groups.
529	In conclusion, we developed a wb-TRS that comprising a panel of genes based on
530	their blood expression levels, and that may involve important biological function
531	pathways was positively associated with nonobese T2D risk and predicted dynamic
532	change in glucose metabolic traits. The study supported that blood transcriptome
533	highly related to and reflect impaired glucose metabolism. It may lend insight into
534	discerning potential causal genes and biological mechanisms in the pathogenesis of
535	nonobese T2D.

536 Acknowledgments

537 We thank all the study participants for their participation and contribution.

538

539 Data availability

- 540 The eQTLs data used in this study are available on the eQLTGen Consortium website
- 541 [https://eqtlgen.org/]. The summary statistics of genome-wide association study of T2D
- 542 was available in the Asian Genetic Epidemiology Network (AGEN)
- 543 [https://blog.nus.edu.sg/agen/] and the DIAbetes Genetics Replication And Meta-
- 544 analysis (DIAGRAM) [http://www.diagram-consortium.org/downloads.html/]. RNA-
- 545 seq related additional data reported in this manuscript are available from the 546 corresponding author upon reasonable request.
- 547

548 **Funding statement**

- 549 This work was funded by the National Natural Science Foundation of China
- 550 (82270859, 91957124, 91857205, 81930021, 81970728, 82070880 and 82088102),
- 551 the Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant
- 552 Support (20152508 Round 2), the Shanghai Shenkang Hospital Development Center
- 553 (SHDC12019101, SHDC2020CR1001A, and SHDC2020CR3064B). MX, JW, ML,
- 554 TW, ZZ, RL, YX, JL, YB, WW, and GN are members of innovative research team of
- 555 high-level local universities in Shanghai.
- 556

557 **Duality of interest**

558 No potential conflicts of interest relevant to this article were reported.

559

560 **Contribution statement**

- 561 M.X., Y.B., and J.W. contributed to the conception and design of the study. Y.H.,
- 562 H.D., and N.C. performed statistical analysis and interpreted data. Y.H., and M.X.
- 563 drafted the manuscript. G.N. and W.W. revised the manuscript critically for important
- 564 intellectual content. Z.Z., Q.W., T.H., J.Z., T.W., M.L., H.L., S.W., R.Z., J.L., Y.X.,
- 565 Y.C., and R.L. contributed to the acquisition of data. All authors were involving in
- revising the manuscript and had final approval of the version to be published. M.X.,
- 567 Y.B. and J.W. are the guarantors of this work and, as such, had full access to all the
- data in the study and take responsibility for the integrity of the data and the accuracy
- 569 of the data analysis.

570 **References**

- 1. IDF Diabetes Atlas 2021 10th edition. <u>www.diabetesatlas.org</u>.
- 572 2. Hahn SJ, Kim S, Choi YS, Lee J, Kang J. Prediction of type 2 diabetes using
- 573 genome-wide polygenic risk score and metabolic profiles: A machine learning analysis
- of population-based 10-year prospective cohort study. EBioMedicine. 2022;86:104383.
- 575 Epub 20221130. doi: 10.1016/j.ebiom.2022.104383. PubMed PMID: 36462406;
- 576 PubMed Central PMCID: PMCPMC9713286.
- 577 3. Wang S, Li M, Lin H, Wang G, Xu Y, Zhao X, et al. Amino acids, microbiota-
- 578 related metabolites, and the risk of incident diabetes among normoglycemic Chinese
- adults: Findings from the 4C study. Cell Rep Med. 2022;3(9):100727. Epub 20220822.
- doi: 10.1016/j.xcrm.2022.100727. PubMed PMID: 35998626; PubMed Central
 PMCID: PMCPMC9512668.
- 4. Padilla-Martinez F, Wojciechowska G, Szczerbinski L, Kretowski A. Circulating
- 583 Nucleic Acid-Based Biomarkers of Type 2 Diabetes. Int J Mol Sci. 2021;23(1). Epub
- 584 20211228. doi: 10.3390/ijms23010295. PubMed PMID: 35008723; PubMed Central
- 585 PMCID: PMCPMC8745431.
- 5. Mahashweta B, Kun W, Eytan R, Sridhar H. Predicting tissue-specific gene
 expression from whole blood transcriptome. 2021;7:eabd6991.
- 588 6. Yao S, Zhang X, Zou SC, Zhu Y, Li B, Kuang WP, et al. A transcriptome-wide
- association study identifies susceptibility genes for Parkinson's disease. NPJ Parkinsons
- 590 Dis. 2021;7(1):79. Epub 20210909. doi: 10.1038/s41531-021-00221-7. PubMed PMID:
- 591 34504106; PubMed Central PMCID: PMCPMC8429416.

592	7. Wang B, Lunetta KL, Dupuis J, Lubitz SA, Trinquart L, Yao L, et al. Integrative
593	Omics Approach to Identifying Genes Associated With Atrial Fibrillation. Circ Res.
594	2020;126(3):350-60. Epub 20191205. doi: 10.1161/CIRCRESAHA.119.315179.
595	PubMed PMID: 31801406; PubMed Central PMCID: PMCPMC7004281.
596	8. Moll M, Boueiz A, Ghosh AJ, Saferali A, Lee S, Xu Z, et al. Development of a
597	Blood-based Transcriptional Risk Score for Chronic Obstructive Pulmonary Disease.
598	Am J Respir Crit Care Med. 2022;205(2):161-70. doi: 10.1164/rccm.202107-1584OC.
599	PubMed PMID: 34739356; PubMed Central PMCID: PMCPMC8787248.
600	9. Li X, Su X, Liu J, Li H, Li M, and Me Research T, et al. Transcriptome-wide
601	association study identifies new susceptibility genes and pathways for depression.
602	Transl Psychiatry. 2021;11(1):306. Epub 20210521. doi: 10.1038/s41398-021-01411-
603	w. PubMed PMID: 34021117; PubMed Central PMCID: PMCPMC8140098.
604	10. Teufel F, Seiglie JA, Geldsetzer P, Theilmann M, Marcus ME, Ebert C, et al. Body-
605	mass index and diabetes risk in 57 low-income and middle-income countries: a cross-
606	sectional study of nationally representative, individual-level data in 685 616 adults. The
607	Lancet. 2021;398(10296):238-48. doi: 10.1016/s0140-6736(21)00844-8.
608	11. Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes:
609	the personal fat threshold. Clin Sci (Lond). 2015;128(7):405-10. doi:
610	10.1042/CS20140553. PubMed PMID: 25515001.
611	12. Zou X, Zhou X, Zhu Z, Ji L. Novel subgroups of patients with adult-onset diabetes

- 612 in Chinese and US populations. The Lancet Diabetes & Endocrinology. 2019;7(1):9-11.
- 613 doi: 10.1016/s2213-8587(18)30316-4.

614	13.	Zaharia (ЭP,	Strassburger K	, Strom A	, Bönhof GJ	, Karusheva Y	, Antoniou S	, et al.
-----	-----	-----------	-----	----------------	-----------	-------------	---------------	--------------	----------

- Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes:
- a 5-year follow-up study. The Lancet Diabetes & Endocrinology. 2019;7(9):684-94. doi:
- 617 10.1016/s2213-8587(19)30187-1.
- 14. Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al.
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-
- 620 driven cluster analysis of six variables. The Lancet Diabetes & Endocrinology.
- 621 2018;6(5):361-9. doi: 10.1016/s2213-8587(18)30051-2.
- 622 15. Wesolowska-Andersen A, Brorsson CA, Bizzotto R, Mari A, Tura A, Koivula R, et
- al. Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity
- 624 in newly diagnosed individuals: An IMI DIRECT study. Cell Rep Med.
- 625 2022;3(1):100477. Epub 20220104. doi: 10.1016/j.xcrm.2021.100477. PubMed PMID:
- 626 35106505; PubMed Central PMCID: PMCPMC8784706.
- 627 16. Spracklen CN, Horikoshi M, Kim YJ, Lin K, Bragg F, Moon S, et al. Identification
- of type 2 diabetes loci in 433,540 East Asian individuals. Nature. 2020;582(7811):240-
- 629 5. Epub 20200506. doi: 10.1038/s41586-020-2263-3. PubMed PMID: 32499647;
- 630 PubMed Central PMCID: PMCPMC7292783.
- 17. Wang B, Li M, Zhao Z, Lu J, Chen Y, Xu Y, et al. Urinary bisphenol A concentration
- and glucose homeostasis in non-diabetic adults: a repeated-measures, longitudinal study.
- 633 Diabetologia. 2019;62(9):1591-600. doi: 10.1007/s00125-019-4898-x.
- 18. Hao M, Ding L, Xuan L, Wang T, Li M, Zhao Z, et al. Urinary bisphenol A
- 635 concentration and the risk of central obesity in Chinese adults: A prospective study. J

- 636 Diabetes. 2018;10(6):442-8. Epub 20170329. doi: 10.1111/1753-0407.12531. PubMed
- 637 PMID: 28097815.
- 638 19. Ning G, Bi Y, Wang T, Xu M, Xu Y, Huang Y, et al. Relationship of Urinary
- 639 Bisphenol A Concentration to Risk for Prevalent Type 2 Diabetes in Chinese Adults.
- 640 Annals of Internal Medicine. 2011 Sep 20;155(6):368-74.
- 641 20. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes
- 642 Care. 2010;33 Suppl 1:S62-9. doi: 10.2337/dc10-S062. PubMed PMID: 20042775;
- 643 PubMed Central PMCID: PMCPMC2797383.
- 644 21. Juergen C, Matthias M. 1D and 2D annotation enrichment: a statistical method
- 645 integrating quantitative proteomics with complementary high-throughput data. BMC
- 646 Bioinformatics. 2012;13(Suppl 16):**S12**.
- 647 22. Fabregat A, Sidiropoulos K, Viteri G, Forner O, Marin-Garcia P, Arnau V, et al.
- 648 Reactome pathway analysis: a high-performance in-memory approach. BMC
- 649 Bioinformatics. 2017;18(1):142. Epub 20170302. doi: 10.1186/s12859-017-1559-2.
- 650 PubMed PMID: 28249561; PubMed Central PMCID: PMCPMC5333408.
- 23. Luo Y, Wang J, Sun L, Gu W, Zong G, Song B, et al. Isocaloric-restricted 651 Mediterranean Diet and Chinese Diets High or Low in Plants in Adults With 652 Prediabetes. J Clin Endocrinol Metab. 2022;107(8):2216-27. 653 doi: 10.1210/clinem/dgac303. PubMed PMID: 35579171; PubMed Central PMCID: 654 PMCPMC9282247. 655
- 656 24. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide
 657 association study identifies novel risk loci for type 2 diabetes. Nature.

658	2007;445(7130):881-5.	Epub	20070211.	doi:	10.1038/nature05616.	PubMed	PMID:
659	17293876.						

- 660 25. Porcu E, Rueger S, Lepik K, e QC, Consortium B, Santoni FA, et al. Mendelian
- 661 randomization integrating GWAS and eQTL data reveals genetic determinants of
- 662 complex and clinical traits. Nat Commun. 2019;10(1):3300. Epub 20190724. doi:
- 663 10.1038/s41467-019-10936-0. PubMed PMID: 31341166; PubMed Central PMCID:
- 664 PMCPMC6656778.
- 665 26. Hu X, Qiao D, Kim W, Moll M, Balte PP, Lange LA, et al. Polygenic transcriptome
- risk scores for COPD and lung function improve cross-ethnic portability of prediction
- 667 in the NHLBI TOPMed program. Am J Hum Genet. 2022;109(5):857-70. Epub
- 668 20220405. doi: 10.1016/j.ajhg.2022.03.007. PubMed PMID: 35385699; PubMed
- 669 Central PMCID: PMCPMC9118106.
- 670 27. Liang Y, Pividori M, Manichaikul A, Palmer AA, Cox NJ, Wheeler HE, et al.
- 671 Polygenic transcriptome risk scores (PTRS) can improve portability of polygenic risk
- 672 scores across ancestries. Genome Biol. 2022;23(1):23. Epub 20220113. doi:
- 673 10.1186/s13059-021-02591-w. PubMed PMID: 35027082; PubMed Central PMCID:

674 PMCPMC8759285.

675 28. Marigorta UM, Denson LA, Hyams JS, Mondal K, Prince J, Walters TD, et al.

- 676 Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn's
- 677 disease. Nat Genet. 2017;49(10):1517-21. Epub 20170814. doi: 10.1038/ng.3936.
- PubMed PMID: 28805827; PubMed Central PMCID: PMCPMC5745037.
- 679 29. Nica AC, Montgomery SB, Dimas AS, Stranger BE, Beazley C, Barroso I, et al.

680	Candidate causal regulatory effects by integration of expression QTLs with complex
681	trait genetic associations. PLoS Genet. 2010;6(4):e1000895. Epub 20100401. doi:
682	10.1371/journal.pgen.1000895. PubMed PMID: 20369022; PubMed Central PMCID:
683	PMCPMC2848550.
684	30. Luigi F, Timothy E MS, Klein., John O H. Long-term calorie restriction is highly
685	effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA.
686	2004;101 (17):6659–63.
687	31. Kraus WE, Bhapkar M, Huffman KM, Pieper CF, Krupa Das S, Redman LM, et al.
688	2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory
689	outcomes of a multicentre, phase 2, randomised controlled trial. The Lancet Diabetes
690	& Endocrinology. 2019;7(9):673-83. doi: 10.1016/s2213-8587(19)30151-2.
691	32. Huffman KM, Parker DC, Bhapkar M, Racette SB, Martin CK, Redman LM, et al.
692	Calorie restriction improves lipid-related emerging cardiometabolic risk factors in
693	healthy adults without obesity: Distinct influences of BMI and sex from CALERIE a
694	multicentre, phase 2, randomised controlled trial. EClinicalMedicine. 2022;43:101261.
695	Epub 20220103. doi: 10.1016/j.eclinm.2021.101261. PubMed PMID: 35028547;
696	PubMed Central PMCID: PMCPMC8741476.
697	33. Ni Q, Sun J, Wang Y, Wang Y, Liu J, Ning G, et al. mTORC1 is required for
698	epigenetic silencing during beta-cell functional maturation. Mol Metab.
699	2022;64:101559. Epub 20220805. doi: 10.1016/j.molmet.2022.101559. PubMed PMID:
700	35940555; PubMed Central PMCID: PMCPMC9418906.
701	34. Cho YS, Chen CH, Hu C, Long J, Ong RT, Sim X, et al. Meta-analysis of genome-

702 wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat

- 703 Genet. 2011;44(1):67-72. Epub 20111211. doi: 10.1038/ng.1019. PubMed PMID:
- 704 22158537; PubMed Central PMCID: PMCPMC3582398.
- 705 35. Siddiqui MK, Anjana RM, Dawed AY, Martoeau C, Srinivasan S, Saravanan J, et
- al. Young-onset diabetes in Asian Indians is associated with lower measured and

genetically determined beta cell function. Diabetologia. 2022;65(6):973-83. Epub

- 708 20220305. doi: 10.1007/s00125-022-05671-z. PubMed PMID: 35247066; PubMed
- 709 Central PMCID: PMCPMC9076730.
- 36. Lai CQ, Parnell LD, Smith CE, Guo T, Sayols-Baixeras S, Aslibekyan S, et al.
 Carbohydrate and fat intake associated with risk of metabolic diseases through
 epigenetics of CPT1A. Am J Clin Nutr. 2020;112(5):1200-11. doi:
 10.1093/ajcn/nqaa233. PubMed PMID: 32930325; PubMed Central PMCID:
- 714 PMCPMC7657341.

- 37. Meng ZX, Yin Y, Lv JH, Sha M, Lin Y, Gao L, et al. Aberrant activation of liver X
 receptors impairs pancreatic beta cell function through upregulation of sterol regulatory
 element-binding protein 1c in mouse islets and rodent cell lines. Diabetologia.
 2012;55(6):1733-44. Epub 20120314. doi: 10.1007/s00125-012-2516-2. PubMed
 PMID: 22415588.
- 38. Wang JQ, Li LL, Hu A, Deng G, Wei J, Li YF, et al. Inhibition of ASGR1 decreases
- 121 lipid levels by promoting cholesterol excretion. Nature. 2022;608(7922):413-20. Epub
- 722 20220803. doi: 10.1038/s41586-022-05006-3. PubMed PMID: 35922515.
- 723 39. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of

724	cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction.
725	Diabetes. 2007;56(9):2328-38. Epub 20070615. doi: 10.2337/db07-0056. PubMed
726	PMID: 17575085.
727	40. Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al.
728	Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in
729	tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and
730	COVID-19 risk factors. Allergy. 2020;75(11):2829-45. Epub 20200824. doi:
731	10.1111/all.14429. PubMed PMID: 32496587; PubMed Central PMCID:
732	PMCPMC7300910.

734 Supporting information

- 735 **Table S1.** Clinical characteristics of study participants.
- 736 Table S2. Weights of 144 gene transcripts included in wb-TRS, ordered from most
- negative to most positive associated with nonobese type 2 diabetes.
- 738 **Table S3.** Receiver operator characteristic curves for prediction of nonobese type 2
- 739 diabetes.
- 740 **Table S4.** Top30 Reactome pathways associated with genes in wb-TRS.
- 741 **Table S5.** Transcriptome wide Mendelian randomization shows the causal effect of
- gene transcripts included in wb_TRS on type 2 diabetes.
- 743 Fig S1. Flowchart of study participants.
- 744 Fig S2. Cross-validation results for least absolute shrinkage and selection operator
- 745 (LASSO) logistics-model for nonobese type 2 diabetes in training dataset.
- Fig S3. Violin plot of wb-TRS and gene transcripts most negatively (FUOM) and
- 747 positively (RPF1) associated with nonobese type 2 diabetes.
- Fig S4. Stratified analysis. Data are odds ratio (OR) and 95% confidence interval (CI)
- 749 calculated using multivariable logistic regression models. The results were adjusted for
- 750 age, sex, body mass index, family history of diabetes, waist circumference, smoking
- 751 and drinking status, education level, physical activity, systolic and diastolic blood
- pressure, total cholesterol, triglycerides, high-density and low-density lipoprotein
- 753 cholesterol.

754 Figure Legends

755	Fig 1. The schematic study design. At the final follow-up visit (10-year's), the
756	whole blood samples of the participants with BMI <25 kg/m ² during the past 10 years
757	were collected and underwent RNA sequencing (RNA-seq). The 1105 nonobese
758	participants with RNA-seq data were randomly split into training (75%) and testing
759	(25%) set. Transcripts with gene expression level >1 CPM in 99% of T2D cases or
760	non-T2D controls and with a nominal difference P value <0.01 between these two
761	groups in the wb-TRS features screening progress. In training dataset, we trained the
762	LASSO logistic-model and adopted 10-fold cross-validation to conduct the
763	transcriptional risk score (wb-TRS). In testing and external dataset, we tested the
764	performance of wb-TRS. Finally, Mitch analysis and Reactome pathway analysis
765	were performed to identify key genes and pathways. Abbreviations: T2D, type 2
766	diabetes; BMI, body mass index; CPM, counts per million; LASSO, least absolute
767	shrinkage and selection operator; TRS, transcriptional risk score; Mitch analysis,
768	multi-contrast gene set enrichment analysis.
769	Fig 2. Restricted cubic spline analysis for associations between the wb-TRS and
770	cardiometabolic traits in testing dataset. Data were adjusted for age, sex, body
771	mass index, family history of diabetes, waist circumference, smoking and drinking
772	status, education level, physical activity, systolic and diastolic blood pressure,
773	triglycerides, low-density lipoprotein cholesterol and anti-diabetic therapy.
774	Fig 3. Receiver operator characteristic curves for prediction of type 2 diabetes.
775	Primary model comprised age, sex, BMI and family history of diabetes.

776	Abbreviations: wb-TRS, whole blood-based transcriptional risk score; BMI, body
777	mass index; FBG, fasting glucose index; TG, triglycerides; and AUC, area under the
778	curve.
779	Fig 4. Mitch analysis. The gene expression level in the top and bottom tertile of the
780	wb-TRS were compared with those in the middle tertile. A, a heatmap of enrichment
781	scores for gene expression contrasts between these two comparisons with hierarchical
782	clustering. Cells in red indicate a positive enrichment score, whereas blue indicated a
783	negative enrichment score. B , the significant metabolic pathways. Abbreviations:
784	botVmid, bottom versus middle tertile; topVmid, top versus middle tertile.

786 Fig 1.















Pathways of Mitch analysis



	Tertile 1(-7.0 ~ -2.5)	Tertile 2 (-2.5	~ -1.4)	Tertile 3 (-1.4 ~ -3.9)		$(-1.4 \sim -3.9)$		Each 1-unit	
	/	OR (95% CI)	P value	OR (95% CI)	P value	1 for trend	OR (95% CI)	P value	
Type 2 diabetes									
Cases, n (%)	8 (9.0)	21 (23.3)		47 (48.5)			76 (27.5)		
Model 1	1.00 (Ref.)	2.57 (1.05-6.30)	0.04	8.36 (3.56-19.7)	<.0001	<.0001	2.49 (1.84-3.36)	<.0001	
Model 2	1.00 (Ref.)	2.46 (0.95-6.35)	0.06	8.68 (3.51-21.5)	<.0001	<.0001	2.57 (1.86-3.56)	<.0001	
Newly diagnosed	type 2 diabetes								
Cases, n (%)	2 (2.3)	13 (14.4)		19 (19.6)			34 (12.3)		
Model 1	1.00 (Ref.)	6.41 (1.38-29.9)	0.01	17.2 (3.72-79.8)	0.0003	<.0001	2.87 (1.84-4.48)	<.0001	
Model 2	1.00 (Ref.)	6.77 (1.30-35.3)	0.02	20.6 (3.94-108)	0.0003	0.001	3.40 (2.00-5.81)	<.0001	
Type 2 diabetes with duration \geq 5 years									
Cases, n (%)	6 (6.7)	7 (7.8)		27 (27.8)			40 (14.5)		
Model 1	1.00 (Ref.)	1.08 (0.33-3.58)	0.90	5.74 (2.09-15.8)	0.001	0.0002	2.32 (1.62-3.34)	<.0001	
Model 2	1.00 (Ref.)	1.17 (0.33-4.24)	0.81	6.12 (2.00-18.7)	0.002	0.0001	2.33 (1.56-3.48)	<.0001	

Table 1. Adjusted ORs (95% CI) of type 2 diabetes associated with whole blood-based transcriptional risk score (wb-TRS) in testing dataset.

Data were odds ratio (OR), 95% confidence interval (CI) calculated from the multivariable logistic regression models. Model 1: adjusted for age,

sex, body mass index, and family history of diabetes; Model 2: further adjusted for waist circumference, smoking and drinking status, education

level, physical activity, systolic and diastolic blood pressure, total cholesterol, triglycerides, HDL-C, and LDL-C. Abbreviation: HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Table 2. Association of each 1-unit increment in the wb_TRS with cardiometabolic

traits (n=1105)

	Training data	set	Testing dataset	;
	β (SE)	P value	β (SE)	P value
Body mass index, kg/m ²				
Model 1	0.09 (0.06)	0.12	0.08 (0.10)	0.43
Model 2	-0.05 (0.04)	0.22	-0.003 (0.08)	0.97
Waist circumference, cm				
Model 1	0.38 (0.14)	0.01	0.14 (0.23)	0.53
Model 2	0.35 (0.14)	0.01	0.20 (0.24)	0.41
Systolic blood pressure, mmHg				
Model 1	1.52 (0.49)	0.002	0.80 (0.82)	0.33
Model 2	1.00 (0.39)	0.01	0.45 (0.65)	0.49
Diastolic blood pressure, mmHg				
Model 1	0.41 (0.28)	0.14	0.02 (0.47)	0.97
Model 2	-0.07 (0.22)	0.77	-0.35 (0.37)	0.36
Total cholesterol, mmol/l				
Model 1	-0.06 (0.03)	0.03	0.11 (0.05)	0.04
Model 2	-0.01 (0.01)	0.22	-0.002 (0.01)	0.86
Triglycerides, mmol/l				
Model 1	0.09 (0.03)	0.001	0.06 (0.03)	0.08
Model 2	0.09 (0.03)	0.001	0.04 (0.03)	0.29
HDL-C, mmol/l				
Model 1	-0.02 (0.01)	0.01	0.02 (0.01)	0.25
Model 2	-0.01 (0.01)	0.43	0.01 (0.01)	0.43
LDL-C, mmol/l				
Model 1	-0.04 (0.02)	0.03	0.08 (0.04)	0.04
Model 2	-0.06 (0.02)	0.01	0.06 (0.04)	0.12
Fasting glucose, mmol/l				
Model 1	0.42 (0.03)	<.0001	0.34 (0.06)	<.0001
Model 2	0.25 (0.03)	<.0001	0.23 (0.06)	<.0001
2h-OGTT glucose, mmol/l				

Model 1	1.16 (0.08)	<.0001	0.84 (0.13)	<.0001
Model 2	1.01 (0.08)	<.0001	0.68 (0.14)	<.0001
HbA1c, %				
Model 1	0.21 (0.02)	<.0001	0.19 (0.04)	<.0001
Model 2	0.07 (0.02)	<.0001	0.10 (0.03)	0.002
Log Fasting insulin, uIU/ml				
Model 1	0.03 (0.005)	<.0001	0.0003 (0.01)	0.97
Model 2	0.01 (0.01)	0.02	-0.004 (0.01)	0.61
Log HOMA-IR				
Model 1	0.05 (0.01)	<.0001	0.02 (0.01)	0.02
Model 2	0.03 (0.01)	<.0001	0.01 (0.01)	0.24
Log HOMA-β				
Model 1	-0.04 (0.01)	<.0001	-0.05 (0.01)	<.0001
Model 2	-0.03 (0.01)	<.0001	-0.04 (0.01)	<.0001

Data were β and standard error (SE). Liner regression model was used to evaluate associations of the wb_TRS (independent) with cardiometabolic traits (dependent variables). Model 1, adjusted for age, sex, body mass index, and family history of diabetes; Model 2, further adjusted for waist circumference, smoking and drinking status, education level, physical activity, systolic and diastolic blood pressure, triglycerides, LDL-C and anti-diabetic therapy. Abbreviation: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OGTT, oral glucose tolerance test; HbA1c, glycated hemoglobin A1c. HOMA-IR, homeostasis model assessment of insulin resistance; and HOMA- β , homeostasis model assessment of β cell function.

Table 3. The effects of baseline wb-TRS on changes of glucose metabolic traits

	At 3 months		At 6 months	
Glucose metabolic traits	β (SE)	P value	β (SE)	P
OGTT				
\triangle Fasting glucose, mmol/l	-0.01 (0.02)	0.72	0.01 (0.02)	0.64
\triangle 0.5h-OGTT glucose, mmol/l	0.03 (0.05)	0.51	-0.0005 (0.06)	0.99
\triangle 1h-OGTT glucose, mmol/l	0.03 (0.08)	0.74	0.12 (0.08)	0.15
\triangle 2h-OGTT glucose, mmol/l	0.04 (0.07)	0.59	0.10 (0.07)	0.16
Continuous glucose monitoring (CGM)	1	I		I
\triangle Average glucose, mmol/l	-0.21 (0.45)	0.64	1.42 (0.55)	0.01
\triangle Average daytime glucose, mg/dl	-0.26 (0.48)	0.59	1.55 (0.60)	0.01
\triangle Average nighttime glucose, mg/dl	-0.16 (0.42)	0.71	1.09 (0.48)	0.03
\triangle AUC glucose, mmol*h/l	0.21 (0.45)	0.65	1.41 (0.55)	0.01
\triangle AUC daytime glucose, mmol*h/l	0.26 (0.48)	0.59	1.56 (0.60)	0.01
\triangle AUC nighttime glucose, mmol*h/l	0.16 (0.42)	0.70	0.21 (0.45)	0.65
△Estimated HbA1c	-0.004 (0.02)	0.81	0.05 (0.02)	0.01
\triangle Estimated daytime HbA1c	-0.01 (0.02)	0.55	0.06 (0.02)	0.01
\triangle Estimated nighttime HbA1c	0.01 (0.01)	0.58	0.04 (0.02)	0.03

during the 6-month dietary intervention (n=253)

Data were change (β) and standard error (SE). P values were from the general linear models after adjusted for sex, baseline age, body mass index, waist circumference, smoking and drinking status, education level, physical activity, systolic and diastolic blood pressure, triglycerides, LDL-C and baseline values for the respective outcome trait. Change (Δ) level was calculated as the numeric value at follow-up visits minus that at baseline. Estimated HbA1c was calculated using the formula: (average

glucose+46.7)/28.7.